{"classes":[{"categories":[{"measurements":[{"comment":"The median duration of response based on Kaplan-Meier estimate had not been reached. The upper limit was not calculable because an insufficient number of participants reached the event at the time point for the assessment.","groupId":"OG000","lowerLimit":"20.100","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"15"}],"units":"Participants"}],"description":"Duration of response (calculated for responders only) was defined as time from the initial documented response (partial response or better) to confirmed disease progression, based on IMWG criteria.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received 4 mg pomalidomide administered by mouth on Days 1-21 of each 28-day treatment cycle and 40 mg dexamethasone (participants \\> 75 years of age received 20 mg dexamethasone) administered by mouth once per day on Days 1, 8, 15, and 22 of a 28-day cycle until disease progression.","id":"OG000","title":"Pomalidomide Plus Dexamethasone"}],"paramType":"MEDIAN","populationDescription":"Efficacy Evaluable Population includes all participants who met eligibility criteria, took at least one dose of study medication, and had a baseline and a post-baseline efficacy assessment.","reportingStatus":"POSTED","timeFrame":"From the first dose until the final data cut-off date of 25 September 2015; maximum duration on treatment was 80.9 weeks","title":"Kaplan-Meier Estimates of Duration of Response (Later Cut-off Date)","type":"SECONDARY","unitOfMeasure":"weeks"}